News

A Phase 2a clinical trial testing Ventus Therapeutics’ VENT-02 — a novel brain-penetrating oral medication — in adults with mild to moderate Parkinson’s disease has dosed its first patient. The study (NCT06822517), expected to enroll about 30 people with Parkinson’s, is assessing the treatment’s safety, tolerability, effects on…

The number of people with Parkinson’s disease is likely to more than double in the next years, topping 25 million worldwide by 2050, mainly because the world’s population is living longer, a study found. The largest increases are projected to be in East Asia, where nearly 11 million people…

Vestibular-oriented balance training during the middle stages of Parkinson’s disease can improve postural control and reduce the risk of falls in people with mild to moderate disease, a new study found. Unlike standard balance training, which typically focuses on stretches and strengthening practices, vestibular-based exercises are designed to enhance…

Note: This story was updated March 13, 2025, to correct that the company’s proprietary software is not available as a downloadable smartphone app. The U.S. Food and Drug Administration (FDA) has listed MR-005, MedRhythms’ digital therapeutic platform using rhythmic beats to help with walking in…

A daily dose of CPL’36, an oral small molecule in the pipeline of Celon Pharma, may ease symptoms for patients who experience levodopa-induced dyskinesia, or uncontrolled movements as a side effect of the mainstay Parkinson’s disease treatment, within one week. That’s according to data from a Phase 2 clinical…

Rune Labs has launched StrivePD Guardian, a personalized care delivery service to help Parkinson’s disease patients manage their condition more effectively by combining expert coaching with artificial intelligence (AI)-driven health monitoring. The program pairs the StrivePD mobile app with an Apple watch, offering users continuous monitoring of…

Onward Medical has received two grants totaling about $2.5 million to support early feasibility studies assessing whether its implantable spinal stimulation system, called ARC-IM, can lessen mobility difficulties and blood pressure instability in people with Parkinson’s disease. The ARC-IM system — in which targeted stimulation can…

A research advocate diagnosed with Parkinson’s disease and a former nurse with Alzheimer’s disease were among recipients of volunteer awards from the Global Alzheimer’s Platform Foundation (GAP). GAP’s Citizen Scientist Awards acknowledge the contributions of volunteers in clinical trials for neurodegenerative diseases. Each year, GAP’s network of research…

Moving Day, a signature fundraiser for the Parkinson’s Foundation, will join communities this spring to raise awareness and money to support care for people with Parkinson’s disease, and advance research toward better treatments. The events will take place in 33 cities across the U.S. from March 15 to…

Inserting a piece of nerve tissue from a patient’s ankle into the brain during deep brain stimulation (DBS) surgery appears a safe and feasible way to support damaged dopaminergic neurons in Parkinson’s disease, with the goal of slowing symptom progression. That’s according to results from a Phase 1…